Raymedica® Announces Release of Volume IV “Emerging Technology” of the 4-Part Series on “Nucleus Arthroplasty Technology in Spinal Care.”

MINNEAPOLIS, (October 23, 2007) — Raymedica, the Pioneer in Nucleus Arthroplasty announced today the release of the final volume, “Emerging Technology,” of its ground-breaking four-volume series entitled, “Nucleus Arthroplasty Technology in Spinal Care,” will be available at the North American Spine Society (NASS) 22nd Annual Meeting held in Austin, Texas, October 24-26, 2007.    The complimentary publication will be made available at Raymedica Booth #916.

“The objective of this series was to provide the spine community with a baseline knowledge and awareness of this emerging and growing segment of the spinal industry,” stated John J. Viscogliosi, Chairman and CEO of Raymedica.  Mr. Viscogliosi added, “It was an incredible challenge to produce a 4-Volume series on this new and less invasive treatment option for early-stage Degenerative Disc Disease (DDD).”  “Of paramount importance to this development effort was a strong emphasis on education and its direct influence on clinical outcomes,” concluded Mr. Viscogliosi.

Raymedica has created a website to provide access to this and previous published volumes at www.nucleusarthroplasty.com.  Nucleusarthroplasty.com is an educational website designed to provide valuable guidance to spine surgeons as they seek to provide more effective and less invasive options for the treatment of degenerative disc disease (DDD).  The service is free to physicians and the general public at www.nucleusarthroplasty.com 

About Raymedica

Raymedica, based in Minneapolis, Minnesota, is the Pioneer in Nucleus Arthroplasty having developed the world’s first nucleus replacement device in 1996.  Raymedica develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have been unresponsive to non-surgical treatment.  Raymedica’s products are currently available in many countries worldwide, but are limited to investigational use only in the United States. For more information, visit the Company's website at http://www.raymedica.com.